Asset Details
Do you wish to reserve the book?
Melatonin ameliorates age-related sarcopenia by inhibiting fibrogenic conversion of satellite cell
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Melatonin ameliorates age-related sarcopenia by inhibiting fibrogenic conversion of satellite cell
Do you wish to request the book?
Melatonin ameliorates age-related sarcopenia by inhibiting fibrogenic conversion of satellite cell
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Melatonin ameliorates age-related sarcopenia by inhibiting fibrogenic conversion of satellite cell
2024
Overview
The fibrogenic conversion of satellite cells contributes to the atrophy and fibrosis of skeletal muscle, playing a significant role in the pathogenesis of age-related sarcopenia. Melatonin, a hormone secreted by the pineal gland, exhibits anti-aging and anti-fibrotic effects in various conditions. However, the effect of melatonin on satellite cell fate and age-related sarcopenia remains under-explored. Here, we report that melatonin treatment mitigated the loss of muscle mass and strength in aged mice, replenished the satellite cell pool and curtailed muscle fibrosis. When primary SCs were cultured in vitro and subjected to aging induction via
d
-galactose, they exhibited a diminished myogenic potential and a conversion from myogenic to fibrogenic lineage. Notably, melatonin treatment effectively restored the myogenic potential and inhibited this lineage conversion. Furthermore, melatonin attenuated the expression of the fibrogenic cytokine, transforming growth factor-β1, and reduced the phosphorylation of its downstream targets Smad2/3 both in vivo and in vitro. In summary, our findings show melatonin's capacity to counteract muscle decline and inhibit fibrogenic conversion in aging SCs and highlight its potential therapeutic value for age-related sarcopenia.
Graphical Abstract
Publisher
BioMed Central,Springer Nature B.V,BMC
Subject
/ Aging
/ Animals
/ Atrophy
/ Biomedical and Life Sciences
/ Collagen
/ Fibrosis
/ Male
/ Mice
/ Muscle Development - drug effects
/ Muscle, Skeletal - drug effects
/ Muscle, Skeletal - metabolism
/ Muscle, Skeletal - pathology
/ Satellite Cells, Skeletal Muscle - drug effects
